Fareon Clinical Study Interest

Fareon, Inc., a Public Benefit Corporation, has developed a new noninvasive approach to treating cognitive impairment related to Long COVID. Fareon’s first pilot study was conducted at Mount Sinai Hospital in New York, confirming safety and showing evidence of meaningful improvements for study participants who received the active therapy.

Fareon will conduct a large multicenter study across several sites in the US planned for later this year, and we are looking for potential study participants.

If you experience brain fog, memory problems, or thinking problems from Long Covid, you may be interested in participating. If you would like to be contacted about potential participation in a study, please fill out the form below.